IDE397

IDE397 is a potent and selective small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A), an enzyme responsible for the production of S-adenosyl-L-methionine (SAM), a key methyl donor in cellular transmethylation reactions. By inhibiting MAT2A, IDE397 disrupts methionine metabolism, which is particularly critical in cancer cells with methylthioadenosine phosphorylase (MTAP) deletion. These MTAP-deleted tumors are more dependent on the MAT2A pathway for survival and proliferation. IDE397 is being developed as a targeted therapy for solid tumors harboring MTAP deletions, including non-small cell lung cancer (NSCLC), urothelial cancer, esophageal carcinoma, bladder cancer, and other advanced solid malignancies. The drug has shown promising efficacy and tolerability in early-phase clinical trials[1][4][6][7][8].

Other names

MAT2A inhibitor IDE397MAT-2A inhibitor IDE397MAT 2A inhibitor IDE397